ScreenerHero

MNKD MannKind Corporation

NAS · US · Healthcare · Biotechnology · mannkindcorp.com
3.450USD-7.01%Mkt Cap: 1.11B $P/E: —

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.11B USD
Enterprise Value1.52B USD
Revenue (TTM)393.63M USD
Gross Profit261.01M USD
Net Income (TTM)5.86M USD
Revenue/Share1.42 USD
Last Price3.450 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees591
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)29.10
PEG4.39
EV/EBITDA77.58
EV/Revenue3.85
P/S3.03
P/B-17.10
EPS (TTM)-0.14
EPS (Forward)0.13
52W Range
2.23029% of range6.510
52W High6.510 USD
52W Low2.230 USD
Profitability
Gross Margin74.79%
Oper. Margin-0.76%
EBITDA Margin4.96%
Profit Margin1.68%
ROE-11.49%
ROA0.74%
Growth
Revenue Growth42.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF18.25M USD
CapEx (TTM)4.57M USD
FCF Margin10.24%
FCF Yield3.63%
Net Debt322.70M USD
Net Debt/EBITDA16.52
Balance Sheet
Debt/Equity-7.20
Current Ratio1.72
Quick Ratio1.29
Book Value/Sh-0.22 USD
Cash/Share0.35 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 3, 2017
Splits
Last Split1:5
Split DateMar 3, 2017
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.969 USD
Upside (mean)+131.0%
Target Range4.750 USD – 13.00 USD
4.750+131.0% to mean13.00
# Analysts8
Ownership
Shares Out.321.54M
Float297.60M
Insiders1.47%
Institutions57.04%
Short Interest
Short Ratio9.2d
Short % Float9.27%
Short % Out.9.14%
Shares Short29.40M
Short (prev mo.)28.58M
Technical
SMA 503.849 (-10.4%)
SMA 2003.959 (-12.9%)
Beta1.08
S&P 52W Chg16.45%
Avg Vol (30d)4.50M
Avg Vol (10d)5.49M
Technical Indicators
RSI (14)41.8
MACD-0.0578
MACD Signal-0.0805
MACD Hist.+0.0227
BB Upper4.142 USD
BB Middle3.638 USD
BB Lower3.134 USD
BB Width27.71%
ATR (14)0.2335 USD
Vol Ratio (20d)1.15x